polycythemia: Abnormally high mass or concentration of red blood cells in the blood, either due to an increase in erythropoiesis or a decrease in plasma volume.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
832 |
4. Check minimum number of eventsNone |
832 |
5. Include endpointsNone |
832 |
6. Filter based on genotype QC (FinnGen only) |
832 |
Control definitions (FinnGen only)
- Control exclude
- D3_BLOODOTHER
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D75
- Name in latin
- Polycythaemia secundaria
Similar endpoints
↥List of similar endpoints to
Secondary polycythaemia
based on the number of shared cases.
Similar with more cases:
- Other diseases of blood and blood-forming organs
- Other diseases of blood and blood-forming organs, wide
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5793 | 1925 | 3795 |
| Only index persons | 4662 | 1564 | 3098 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.09 | 0.06 | 0.11 |
| Only index persons | 0.10 | 0.06 | 0.12 |
| Median age at first event (years) | |||
| Whole population | 58.75 | 60.79 | 57.65 |
| Only index persons | 57.47 | 60.07 | 56.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 832 | 289 | 543 |
| Unadjusted period prevalence (%) | 0.19 | 0.10 | 0.24 |
| Median age at first event (years) | 57.94 | 56.36 | 58.78 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 762
- Matched controls
- 7618
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D75.1
ICD-10 Finland
Secondary polycythaemia
4503599627370496.0
323.0
703
*
D45
ICD-10 Finland
Polycythaemia vera
57.3
85.1
100
20
XW000
NOMESCO Finland
Bone marrow biopsy
13.1
65.7
120
107
TPH00
NOMESCO Finland
Phlebotomy
71.0
46.7
53
8
28900
ICD-8 Finland
Other disease of blood and blood-forming organs, Polycythaemia, secondary
+∞
44.2
42
*
D75.0
ICD-10 Finland
Familial erythrocytosis
+∞
42.1
40
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
+∞
42.1
40
*
SPAT1074
SPAT
Venesection
48.8
38.3
46
10
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
5.0
32.0
110
249
T90
ICPC
Diabetes non-insulin dependent
2.9
31.7
244
1071
G47.3
ICD-10 Finland
Sleep apnoea
2.8
31.2
256
1169
103
Kela drug reimbursment
Diabetes, insulin-treated
2.6
27.7
267
1320
A10BA02
ATC
metformin; oral
2.5
27.1
267
1330
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.6
26.2
233
1095
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.6
25.7
243
1179
R71
ICD-10 Finland
Abnormality of red blood cells
89.6
23.8
26
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.0
22.4
143
542
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
23.1
20.5
29
13
I10
ICD-10 Finland
Essential (primary) hypertension
2.0
18.7
456
3257
SPAT1262
SPAT
Handing over of treatment supplies
2.4
18.6
176
832
D75.2
ICD-10 Finland
Essential thrombocytosis
184.0
17.6
18
*
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.6
17.5
148
655
R5140
NOMESCO Finland
Monitoring the use of the aid
2.8
17.5
122
484
C03DA01
ATC
spironolactone; oral
3.0
17.4
109
405
I50.9
ICD-10 Finland
Heart failure, unspecified
2.7
17.3
133
558
L01XX05
ATC
hydroxycarbamide; oral
16.4
17.1
27
17
A10BH01
ATC
sitagliptin; oral
3.0
17.1
105
383
C03CA01
ATC
furosemide; systemic
2.1
17.0
233
1306
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
2.1
16.9
229
1277
C07AB07
ATC
bisoprolol; oral
1.9
16.9
375
2542
E29.1
ICD-10 Finland
Testicular hypofunction
10.7
16.8
32
31
R03BB04
ATC
tiotropium bromide; inhalant
2.9
16.6
107
403
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
16.3
354
2371
J96.1
ICD-10 Finland
Chronic respiratory failure
6.6
15.7
40
63
SPAT1249
SPAT
Treatment-related counselling outside office
1.9
14.4
296
1918
R03AC02
ATC
salbutamol; inhalant
1.8
14.1
375
2647
C07AB02
ATC
metoprolol; systemic
2.1
13.7
173
925
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.9
13.6
87
327
M04AA01
ATC
allopurinol; systemic
2.4
13.4
121
550
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
3.7
13.4
60
174
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.7
13.4
99
405
A10BK01
ATC
dapagliflozin; oral
4.1
13.1
51
131
B99
ICPC
Blood/lymph/spleen disease other
15.7
12.7
20
13
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
32.6
12.6
16
5
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
2.6
12.5
97
407
205
Kela drug reimbursment
Chronic hypertension
1.9
12.4
225
1377
J44.9
ICD-10 Finland
Chronic obstructive pulmonary disease, unspecified
3.8
12.3
52
144
C01AA05
ATC
digoxin; systemic
2.8
11.9
81
315
C08CA01
ATC
amlodipine; oral
1.8
11.6
274
1825
R06.0
ICD-10 Finland
Dyspnoea
1.9
11.6
188
1104
A10AE04
ATC
insulin glargine; parenteral
2.6
11.6
91
384
2890X
ICD-9 Finland
Other diseases of blood and blood-forming organs, Polycythaemia, secondary[ERYTHROCYTOSIS SECUNDARIA, NUD]
+∞
11.5
11
*
D58.2
ICD-10 Finland
Other haemoglobinopathies
+∞
11.5
11
*
J44.1
ICD-10 Finland
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
4.2
11.2
42
105
121
Kela drug reimbursment
Severe hypofunction of sexual glands
8.0
10.9
24
31
A10BJ02
ATC
liraglutide; parenteral
5.0
10.9
34
70
E66.9
ICD-10 Finland
Obesity, unspecified
4.4
10.7
38
90
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
8.7
10.6
22
26
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
3.2
10.5
54
175
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
111.4
10.4
11
*
N02AX02
ATC
tramadol; systemic, rectal
1.7
10.4
319
2282
E66.00
ICD-10 Finland
Metabolic syndrome
3.3
10.3
52
167
XG466
NOMESCO Finland
Sleep oxymetry
3.6
10.2
45
130
A10BK03
ATC
empagliflozin; oral
2.6
10.2
74
300
E66.01
ICD-10 Finland
Obesity due to excess calories
2.8
10.1
64
239
346
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
3.3
10.1
50
158
R03AK06
ATC
salmeterol and fluticasone; inhalant
2.2
9.9
104
508
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
3.2
9.8
50
162
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.6
9.8
71
286
J44
ICD-10 Finland
Other chronic obstructive pulmonary disease
5.4
9.7
28
53
C02AC05
ATC
moxonidine; oral
3.4
9.7
46
141
207
Kela drug reimbursment
Chronic arrhythmias
2.1
9.7
121
640
C09AA05
ATC
ramipril; oral
1.8
9.6
189
1177
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.0
9.5
123
658
H02AB06
ATC
prednisolone; systemic
1.6
9.4
329
2422
E66.8
ICD-10 Finland
Other obesity
3.3
9.3
46
146
R79.8
ICD-10 Finland
Other specified abnormal findings of blood chemistry
13.9
9.2
15
11
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
1.9
9.0
143
826
M10.9
ICD-10 Finland
Gout, unspecified
2.7
8.9
61
241
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.7
8.9
231
1559
N07BA03
ATC
varenicline; oral
3.0
8.8
50
173
A10BJ06
ATC
semaglutide; parenteral
3.8
8.5
35
96
I27.9
ICD-10 Finland
Pulmonary heart disease, unspecified
27.8
8.5
11
*
Q21.81
ICD-10 Finland
Eisenmenger's syndrome
+∞
8.3
8
*
B01AA03
ATC
warfarin; systemic
1.8
8.2
161
996
E66.2
ICD-10 Finland
Extreme obesity with alveolar hypoventilation
6.1
8.2
21
35
I48
ICD-10 Finland
Atrial fibrillation and flutter
1.7
8.1
177
1131
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
2.0
8.1
102
539
R79.9
ICD-10 Finland
Abnormal finding of blood chemistry, unspecified
11.9
8.1
14
12
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
3.4
8.1
38
117
WX780
NOMESCO Finland
Remote monitoring CPAP
3.0
8.1
44
151
I50.0
ICD-10 Finland
Congestive heart failure
2.5
8.0
61
253
I27.2
ICD-10 Finland
Other secondary pulmonary hypertension
22.3
8.0
11
5
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.8
8.0
164
1029
M54.5
ICD-10 Finland
Low back pain
1.6
7.9
222
1527
C09AA02
ATC
enalapril; systemic
1.8
7.8
151
926
M79.6
ICD-10 Finland
Pain in limb
1.6
7.8
232
1616
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
5.4
7.7
22
42
SPAT1225
SPAT
Implementation of podiatry rehabilitation plan
4.0
7.6
29
75
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
1.9
7.4
122
709
Y28
ICPC
Limited function/disability (Y)
13.5
7.4
12
9
D75.8
ICD-10 Finland
Other specified diseases of blood and blood-forming organs
+∞
7.3
7
*
SPAT1254
SPAT
Administration of medicine
1.9
7.3
103
568
SPAT1148
SPAT
Treatment of chronic ulcer or burn
1.9
7.2
103
571
WX723
NOMESCO Finland
CPAP therapy
3.0
7.2
41
143
A10BB12
ATC
glimepiride; oral
2.4
7.2
59
256
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
1.9
7.1
102
565
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
20.2
7.1
10
5
A02BC02
ATC
pantoprazole; systemic
1.5
7.1
450
3719
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
3.2
7.1
35
113
C10AA01
ATC
simvastatin; oral
1.5
7.0
306
2326
E66
ICD-10 Finland
Obesity
3.3
6.9
32
99
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
1.9
6.8
108
620
201
Kela drug reimbursment
Chronic cardiac insufficiency
2.5
6.8
51
213
SPAT1263
SPAT
Sampling
1.5
6.7
278
2086
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
1.9
6.7
100
562
160
Kela drug reimbursment
exenatide
4.1
6.6
24
60
N06AX11
ATC
mirtazapine; oral
1.6
6.6
221
1577
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
2.6
6.6
44
173
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
2.2
6.6
63
297
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
2.9
6.4
37
131
J45.9
ICD-10 Finland
Asthma, unspecified
1.8
6.4
117
703
D70.82
ICD-10 Finland
Drug-induced neutropenia
70.4
6.4
7
*
R03AL06
ATC
olodaterol and tiotropium bromide; inhalant
5.0
6.4
19
39
C08CA02
ATC
felodipine; oral
2.1
6.2
70
355
L28
ICPC
Limited function/disability (L)
1.8
6.2
105
615
K80.2
ICD-10 Finland
Calculus of gallbladder without cholecystitis
2.0
6.2
76
400
I11.9
ICD-10 Finland
Hypertensive heart disease without (congestive) heart failure
2.7
6.2
38
143
WX110
NOMESCO Finland
Local anesthesy
1.5
6.2
472
4002
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
330
79
68.57
307.65
1.1
1.0
—
—
—
0
0
397
107
70.05
307.65
1.4
1.2
15.6
51.1
u/l
1.17
347
96
250
718
4.55
80.55
2.8
4.0
236.0
249.9
u/l
0.48
231
679
279
875
4.29
79.89
2.3
2.5
25.3
23.4
%
1.21
250
751
283
927
4.11
75.83
2.2
2.4
2.6
2.3
g/l
12.93
260
859
289
1017
3.82
68.99
2.4
2.5
15.6
13.4
umol/l
4.54
266
941
618
3725
3.56
58.40
9.7
9.0
4.6
4.2
e9/l
4.45
558
3249
336
1783
2.48
34.12
3.2
2.6
2875.4
6379.0
umol/l
0.98
295
1558
436
2619
2.40
33.32
3.2
2.7
140.7
149.6
ug/l
0.31
402
2396
373
2108
2.39
32.56
5.0
4.0
13.6
8.7
mg/mmol
1.04
237
1379
522
3427
2.40
32.08
6.7
6.6
14.2
11.6
umol/l
4.82
509
3257
370
2121
2.34
30.82
3.7
3.2
8.3
8.0
mmol/l
0.43
295
1775
61
117
5.55
30.74
2.9
3.2
57.8
57.6
%
0.03
61
117
58
113
5.44
28.71
2.7
2.9
4.5
4.4
e9/l
0.12
58
113
666
5040
2.61
27.49
9.1
7.7
82.2
78.7
u/l
0.85
637
4734
129
505
2.84
23.47
3.7
3.8
1.2
1.2
mmol/l
0.17
116
448
68
185
3.91
22.25
1.7
1.4
6.0
8.4
u/l
1.01
52
150
58
141
4.35
22.06
3.2
2.4
20.3
16.2
%
7.53
33
75
43
81
5.54
22.04
1.9
2.1
33.1
33.2
pg
0.04
43
81
541
3924
2.08
21.91
6.6
5.1
7.2
6.8
mmol/l
3.64
530
3701
433
2910
2.02
21.57
7.1
6.5
1.2
1.2
mmol/l
0.40
397
2638
321
1938
2.07
21.56
3.9
3.0
1466.9
1354.3
ng/l
0.22
267
1635
421
2803
2.02
21.51
4.9
4.9
35.8
35.6
g/l
0.34
387
2604
463
3202
2.01
21.08
7.3
7.1
1.2
1.2
mmol/l
0.08
361
2726
323
1989
2.02
20.26
4.1
3.2
131.9
92.0
e6/l
0.26
258
1537
153
723
2.37
18.67
4.5
2.2
13.7
13.3
nmol/l
0.21
136
651
239
1355
2.07
18.54
3.5
2.6
4.2
4.2
e6/l
0.02
209
1192
294
1811
1.96
17.96
4.0
3.1
0.5
0.5
e6/l
0.00
231
1364
600
4684
2.01
17.75
4.5
3.5
15.2
14.8
pmol/l
2.68
538
4231
607
4803
1.98
16.65
4.2
3.9
7.4
11.9
mm/h
15.64
563
4423
149
752
2.20
15.36
2.5
2.8
9.2
8.8
umol/l
0.09
133
666
101
431
2.53
15.27
4.2
3.5
2.9
1.8
mmol/l
1.94
76
316
63
213
3.12
14.74
2.9
1.9
186.0
212.0
pmol/l
0.97
63
201
345
2372
1.78
14.07
4.0
3.2
—
—
—
0
0
48
141
3.55
14.04
2.2
2.3
162.7
131.4
g/l
10.06
43
105
324
2192
1.78
13.93
3.7
3.5
34.5
34.5
u/l
0.00
314
2078
54
179
3.16
13.06
1.8
3.1
1.5
1.6
mg/l
0.44
43
162
148
792
2.06
12.97
7.7
9.1
1.9
1.1
mmol/l
1.15
117
624
159
876
2.01
12.85
5.6
6.1
1.0
1.0
mmol/l
0.33
152
815
134
696
2.10
12.70
4.9
3.3
—
—
—
0
0
683
5824
1.96
12.53
5.5
4.3
1.9
2.1
mu/l
0.51
610
5281
367
2631
1.71
12.47
5.0
3.5
24.6
45.3
ng/l
3.82
290
1873
226
1453
1.76
11.12
1.9
1.7
0.9
1.2
mg/l
2.36
171
1129
23
46
5.11
11.04
1.6
1.8
18.6
19.6
nmol/l
0.17
23
41
16
22
7.40
11.01
1.6
2.8
199.3
203.6
u/l
0.10
16
22
297
2071
1.68
10.81
2.9
2.6
50.5
57.2
u/l
3.43
270
1935
178
1084
1.82
10.44
2.2
1.8
—
—
—
0
0
250
1688
1.69
10.17
4.5
3.7
0.0
0.0
estimate
0.69
107
556
704
6209
1.87
9.66
8.4
5.8
42.9
40.1
mmol/mol
7.88
640
5771
173
1075
1.77
9.40
3.8
3.4
0.8
0.8
mmol/l
0.43
164
1016
735
6596
1.98
9.24
19.8
14.1
20.2
25.0
mg/l
4.56
645
5235
68
306
2.33
9.12
3.3
3.4
4.6
4.6
pmol/l
0.10
57
275
709
6312
1.83
8.82
20.5
13.0
77.9
81.4
ml/min/173m2
4.13
625
5223
229
1561
1.64
8.78
2.7
2.1
5.3
3.1
mg/l
6.88
198
1330
405
3164
1.55
8.62
4.2
3.5
0.0
0.0
estimate
0.50
109
550
401
3133
1.54
8.48
4.2
3.4
0.0
0.0
estimate
0.00
123
575
400
3127
1.54
8.42
5.3
4.7
0.0
0.0
estimate
0.00
122
584
25
67
3.82
8.39
1.4
1.5
0.2
0.3
nmol/l
0.36
19
53
34
112
3.12
8.36
1.8
1.8
—
—
—
0
0
331
2487
1.55
8.32
2.5
2.2
72.9
75.6
nmol/l
1.04
296
2204
629
5451
1.63
8.27
25.2
17.2
14.4
13.7
%
14.51
620
5337
25
70
3.65
7.90
2.1
1.7
—
—
—
0
0
109
625
1.86
7.65
2.1
2.4
0.2
0.2
g/l
0.49
104
584
324
2460
1.52
7.58
4.2
3.5
—
—
—
0
0
16
34
4.78
7.19
1.4
1.6
—
—
—
0
0
47
201
2.42
7.09
2.9
4.2
37.4
31.9
mg/l
0.40
35
166
47
201
2.42
7.09
2.9
4.2
51.4
91.4
mg/l
0.66
34
164
745
6836
1.86
7.02
24.9
16.6
139.6
139.7
mmol/l
0.31
729
6666
195
1359
1.57
6.60
1.9
1.7
89189615.0
28144666.4
pmol/l
0.46
148
1137
90
509
1.86
6.59
2.3
3.0
64.8
66.5
g/l
1.09
81
465
744
6854
1.81
6.49
25.3
16.7
4.0
4.0
mmol/l
0.12
728
6677
15
33
4.61
6.48
1.4
1.6
—
—
—
0
0
703
6387
1.65
6.34
4.9
4.0
1.6
1.3
mmol/l
12.30
633
5885
282
2148
1.47
6.22
3.4
3.4
2.4
2.3
mmol/l
1.23
245
1867
530
4546
1.46
6.19
3.8
3.2
64.8
53.9
u/l
1.49
486
4265
489
4136
1.44
6.13
5.7
4.2
221.2
1437.4
e6/l
0.54
11
62
102
615
1.75
6.05
4.6
3.6
2.1
2.1
mmol/l
0.03
81
489
331
2613
1.44
6.00
1.9
2.0
89.6
93.9
pmol/l
0.99
185
1387
720
6617
1.65
5.77
5.4
4.4
1.2
1.4
mmol/l
40.61
653
6109
33
132
2.56
5.76
3.8
2.9
0.8
0.9
nmol/l
0.39
26
105
723
6660
1.65
5.64
5.4
4.4
4.4
4.6
mmol/l
9.67
661
6185
20
61
3.33
5.61
2.4
2.3
572.3
651.3
ml
0.57
12
38
733
6778
1.68
5.60
6.1
4.9
2.6
2.8
mmol/l
3.13
664
6254
36
154
2.40
5.48
1.8
1.7
—
—
—
0
0
89
532
1.75
5.44
3.5
2.9
297.0
186.9
ng/l
1.57
78
481
264
2032
1.44
5.36
2.4
2.1
283.2
275.8
u/l
0.03
239
1916
136
913
1.59
5.34
1.9
1.9
1.5
1.5
%
0.03
116
801
118
766
1.63
5.31
2.1
1.8
—
—
—
0
0
117
761
1.63
5.23
2.0
1.8
—
—
—
0
0
35
152
2.36
5.16
1.8
1.7
—
—
—
0
0
25
92
2.77
5.14
2.1
1.6
—
—
—
0
0
236
1792
1.44
5.12
1.7
1.7
1.8
1.4
mmol/l
3.11
174
1516
15
40
3.80
5.11
1.4
1.6
—
—
—
0
0
8
6
13.44
5.08
1.0
1.0
—
—
—
0
0
17
50
3.45
5.05
1.9
1.5
—
—
—
0
0
129
867
1.58
5.03
37.9
22.4
1.9
1.3
inr
3.02
23
120
39
181
2.21
4.95
1.7
1.5
292.9
272.6
ug/g
0.21
22
109
24
90
2.72
4.78
1.6
1.7
—
—
—
0
0
57
313
1.88
4.61
5.2
3.9
23.8
24.2
mmol/l
0.39
48
280
74
442
1.74
4.56
4.2
4.1
97.2
90.5
ng/l
0.27
59
392
20
70
2.90
4.52
1.9
1.3
113.1
57.6
pmol/l
0.63
14
21
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
44
224
2.02
4.43
4.3
2.6
0.4
0.3
u/ml
0.61
31
111
23
89
2.63
4.33
1.3
1.6
—
—
—
0
0
160
1162
1.47
4.32
3.0
3.2
2.5
2.4
mmol/l
2.40
131
1019
39
194
2.06
4.19
2.4
2.4
45.6
100.1
ug/min
1.38
19
116
753
7109
1.62
4.10
14.2
10.3
34.1
28.5
u/l
3.54
724
6873
698
6485
1.47
4.08
6.0
4.5
6.5
6.0
mmol/l
10.96
626
5922
8
10
8.06
4.06
1.3
1.5
—
—
—
0
0
29
132
2.24
3.90
1.7
1.8
3.1
5.8
iu/l
1.27
11
40
15
49
3.10
3.82
18.8
17.6
1166.7
1455.5
nmol/l
0.86
15
49
30
141
2.17
3.75
1.3
1.2
9.6
12.6
e6/l
0.13
25
110
46
255
1.85
3.66
5.0
4.1
1.4
1.4
mmol/l
0.13
46
248
142
1046
1.43
3.54
2.7
2.1
32.6
29.8
s
3.22
137
1017
23
100
2.34
3.45
1.3
1.5
—
—
—
0
0
37
195
1.94
3.44
1.7
1.6
—
—
—
0
0
25
116
2.19
3.25
1.6
1.6
—
—
—
0
0
33
171
1.97
3.23
1.2
1.2
—
—
—
0
0
150
1134
1.39
3.22
3.6
2.8
1.0
1.0
e6/l
0.02
94
654
22
97
2.30
3.22
1.1
1.1
—
—
—
0
0
163
1269
1.35
2.91
1.2
1.2
1.1
1.9
u/ml
0.66
52
359
153
1182
1.36
2.87
1.9
1.7
1132.7
1167.9
nmol/l
0.18
113
886
140
1074
1.36
2.75
3.7
2.9
2.1
1.5
e6/l
0.27
82
596
89
632
1.46
2.71
2.3
2.5
30.9
33.2
u/l
0.40
77
542
11
37
3.00
2.70
1.2
1.1
—
—
—
0
0
64
426
1.54
2.66
1.7
1.6
—
—
—
0
0
161
1274
1.33
2.58
5.1
3.7
1849.6
409.1
ng/l
0.43
125
1020
15
62
2.45
2.55
1.4
1.2
—
—
—
0
0
23
115
2.03
2.53
1.1
1.1
252.6
9.4
iu/ml
—
7
25
124
948
1.36
2.49
1.5
1.4
—
—
—
0
0
25
132
1.92
2.38
1.2
1.1
—
—
—
0
0
646
6075
1.28
2.35
22.5
15.0
45.8
40.6
%
20.00
410
4411
24
126
1.93
2.32
1.2
1.2
334.6
292.7
u/ml
0.28
18
73
27
148
1.85
2.31
1.5
1.5
—
—
—
0
0
44
280
1.60
2.24
4.4
4.1
25.0
24.9
mmol/l
0.08
39
262
342
3016
1.23
2.20
4.8
4.0
—
—
—
0
0
353
3127
1.22
2.17
4.7
4.6
1.8
2.4
ug/l
1.98
315
2812
30
174
1.75
2.16
3.0
3.1
0.0
0.0
g/l
0.00
30
161
16
74
2.18
2.15
2.9
3.2
5.2
5.6
nmol/l
0.06
16
74
25
137
1.85
2.15
3.4
3.8
9.9
24.1
mg/l
4.21
17
87
7
19
3.71
2.15
1.0
1.4
—
—
—
0
0
15
68
2.23
2.12
1.3
1.3
—
—
—
0
0
30
176
1.73
2.08
3.0
3.1
0.0
0.0
g/l
0.00
30
162
15
69
2.20
2.05
1.0
1.1
—
—
—
0
0
12
50
2.42
2.03
1.5
1.2
11.7
13.4
mmol/l
—
7
19
31
188
1.67
1.93
3.2
3.1
0.0
0.0
g/l
0.06
31
174
10
39
2.58
1.92
1.0
1.1
0.9
1.1
u/l
—
5
18
52
359
1.48
1.88
1.3
1.2
159.2
147.5
iu/ml
0.05
14
142
35
222
1.60
1.85
3.0
2.8
10.2
10.6
g/l
0.23
35
192
69
505
1.40
1.84
2.0
1.9
—
—
—
0
0
6
17
3.55
1.84
2.5
1.5
—
—
—
0
0
6
17
3.55
1.84
1.0
1.1
—
—
—
0
0
180
1510
1.25
1.81
1.5
1.5
18.5
20.0
nmol/l
0.81
157
1276
41
274
1.52
1.75
1.0
1.0
—
—
—
0
0
9
36
2.52
1.74
1.6
3.8
65.7
84.0
nmol/l
—
9
36
31
194
1.62
1.74
3.2
2.9
37.2
37.4
g/l
0.06
31
168
25
148
1.71
1.72
1.4
1.2
—
—
—
0
0
5
13
3.86
1.71
1.0
2.1
50.8
87.4
%
—
5
7
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
5
13
3.86
1.71
1.0
1.1
48.2
110.4
%
—
5
13
5
13
3.86
1.71
1.0
1.1
44.0
96.0
%
—
5
7
42
284
1.50
1.70
1.9
1.9
0.8
2.4
ug/l
0.92
36
247
37
244
1.54
1.68
2.9
2.7
—
—
—
0
0
81
619
1.34
1.68
2.6
2.3
10.2
7.7
ug/l
0.26
69
555
762
7408
1.34
1.56
32.9
20.5
5.3
4.6
e12/l
117.60
749
7200
762
7410
1.34
1.54
33.2
20.6
156.5
138.0
g/l
99.81
753
7295
18
100
1.82
1.54
1.4
1.2
5.0
6.6
u/ml
—
9
45
39
267
1.48
1.51
2.1
1.9
—
—
—
0
0
25
154
1.64
1.51
1.2
1.4
156.6
214.1
miu/ml
—
8
71
14
72
1.96
1.49
1.0
1.1
—
—
—
0
0
41
286
1.46
1.46
1.9
2.0
42.3
38.5
u/l
0.49
35
250
25
156
1.62
1.45
1.3
1.3
—
—
—
0
0
72
555
1.33
1.43
2.0
1.9
—
—
—
0
0
433
4013
1.16
1.40
3.0
2.8
—
—
—
0
0
35
241
1.47
1.34
2.0
1.8
—
—
—
0
0
8
34
2.37
1.29
1.0
1.0
—
—
—
0
0
27
179
1.53
1.25
2.3
2.9
31.1
35.0
umol/l
0.40
22
148
6
25
2.41
1.24
2.8
4.0
—
—
—
0
0
6
25
2.41
1.24
1.2
1.2
—
—
—
0
0
9
45
2.01
1.23
1.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
19
2.64
1.21
1.0
2.7
136.8
124.1
%
—
5
19
8
38
2.12
1.18
1.0
1.0
—
—
—
0
0
12
64
1.89
1.18
1.0
1.1
—
—
u/ml
—
0
0
0
34
0.00
1.16
0.0
1.2
—
—
—
0
0
13
72
1.82
1.15
1.2
1.9
—
—
—
0
0
52
397
1.33
1.14
1.7
1.4
—
—
—
0
0
8
40
2.01
1.12
2.6
3.0
—
—
—
0
0
12
66
1.83
1.09
1.2
2.0
—
—
—
0
0
8
41
1.96
1.09
2.9
2.4
—
—
—
0
0
7
32
2.20
1.08
1.1
1.2
34.9
23.1
u/l
—
7
23
7
32
2.20
1.08
1.1
1.2
118.5
87.8
u/l
—
7
23
13
74
1.77
1.07
1.0
1.1
—
—
—
0
0
7
33
2.13
1.05
1.1
1.1
179.3
288.0
iu/ml
—
7
33
7
33
2.13
1.05
1.6
1.4
—
—
—
0
0
41
307
1.35
1.04
1.1
1.3
—
—
—
0
0
11
60
1.84
1.03
3.2
2.6
—
—
—
0
0
7
34
2.07
1.03
1.1
1.8
—
—
—
0
0
7
34
2.07
1.03
1.1
1.8
—
—
—
0
0
7
34
2.07
1.03
1.1
1.8
—
—
—
0
0
7
34
2.07
1.03
1.1
1.8
—
—
—
0
0
19
123
1.56
1.00
1.8
1.3
—
—
—
0
0
19
123
1.56
1.00
1.8
1.3
—
—
—
0
0
7
132
0.53
0.99
1.4
1.4
—
—
—
0
0
275
2519
1.14
0.98
4.1
3.9
22.0
21.0
%
0.56
127
1117
50
631
0.78
0.94
1.8
1.8
—
—
—
0
0
11
62
1.78
0.94
1.1
1.7
—
—
—
0
0
11
62
1.78
0.94
1.1
1.7
—
—
—
0
0
11
62
1.78
0.94
1.1
1.7
—
—
—
0
0
6
28
2.15
0.91
1.2
2.9
70.0
101.1
%
—
6
28
83
695
1.22
0.90
4.0
4.5
4.7
26.7
ug/l
1.18
75
586
32
237
1.36
0.89
2.4
3.2
—
—
—
0
0
26
187
1.40
0.86
1.0
1.1
—
—
—
0
0
56
455
1.25
0.82
1.5
1.6
—
—
—
0
0
26
189
1.39
0.82
1.0
1.1
—
—
—
0
0
22
156
1.42
0.79
1.2
1.1
—
—
—
0
0
8
48
1.67
0.79
1.3
1.4
—
24.4
—
0
7
6
34
1.77
0.76
1.0
1.1
—
—
—
0
0
15
99
1.52
0.76
2.1
2.6
—
489.2
—
0
9
13
83
1.58
0.75
1.2
1.1
—
—
—
0
0
5
25
2.01
0.72
1.0
1.0
2023.4
1541.6
miu/ml
—
5
25
18
126
1.44
0.70
1.2
1.1
—
—
—
0
0
10
61
1.65
0.68
1.0
1.1
—
—
—
0
0
7
42
1.67
0.68
1.3
1.2
—
—
—
0
0
10
156
0.64
0.68
1.1
1.4
—
—
—
0
0
15
102
1.48
0.68
1.1
1.3
—
—
—
0
0
7
43
1.63
0.67
1.0
1.2
—
—
—
0
0
5
30
1.67
0.61
1.8
1.3
—
—
—
0
0
8
52
1.54
0.59
1.1
1.2
—
—
—
0
0
34
273
1.26
0.59
2.2
3.8
146.2
5111.1
u/ml
0.74
28
232
23
178
1.30
0.53
1.7
1.6
—
—
—
0
0
9
63
1.43
0.52
2.6
1.9
—
—
—
0
0
24
189
1.28
0.50
1.3
1.3
—
—
—
0
0
73
825
0.87
0.49
5.0
4.6
27.3
31.1
%
2.92
53
553
53
612
0.86
0.48
1.3
1.4
—
—
—
0
0
7
50
1.40
0.45
1.1
1.1
—
—
—
0
0
7
50
1.40
0.45
1.1
1.1
—
—
—
0
0
10
69
1.45
0.44
1.1
1.4
11.2
26.5
u/l
—
10
56
7
51
1.38
0.44
1.1
1.1
—
—
—
0
0
7
51
1.38
0.44
1.1
1.1
—
—
—
0
0
7
51
1.38
0.44
1.1
1.1
—
—
—
0
0
5
35
1.43
0.39
1.0
1.3
—
—
—
0
0
5
35
1.43
0.39
1.0
1.3
—
—
—
0
0
19
151
1.26
0.38
1.1
1.5
—
—
—
0
0
9
66
1.37
0.38
1.1
1.1
—
—
—
0
0
21
172
1.23
0.34
1.4
1.6
16385.4
16519.5
e6/l
0.01
14
127
113
1051
1.09
0.33
1.3
1.3
16.0
31.6
iu/ml
3.68
37
314
16
197
0.81
0.31
1.5
1.6
0.0
0.1
iu/ml
—
5
37
7
56
1.25
0.29
1.0
1.3
—
—
—
0
0
9
72
1.25
0.25
3.0
4.0
—
—
—
0
0
27
235
1.15
0.25
2.6
2.7
23.5
49.3
u/ml
1.19
27
224
11
87
1.27
0.24
1.1
1.1
—
—
—
0
0
5
40
1.25
0.22
1.0
1.2
14.6
12.8
u/l
—
5
33
106
1003
1.07
0.22
1.2
1.3
3.7
10.9
u/ml
1.80
43
400
165
1583
1.05
0.22
2.6
2.4
—
—
—
0
0
21
241
0.87
0.21
1.6
1.6
2.5
3.3
mg/l
0.33
16
176
5
42
1.19
0.21
1.0
1.2
63.2
72.9
u/l
—
5
36
0
10
0.00
0.21
0.0
2.9
—
76.9
—
0
10
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
190
1832
1.05
0.21
3.1
2.8
0.7
0.7
ug/l
0.17
125
1143
5
43
1.16
0.21
1.6
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
147
1409
1.05
0.20
4.1
3.7
1.0
1.0
kg/l
1.06
28
201
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
18
157
1.15
0.17
12.2
10.0
104.7
105.4
mmol/l
0.27
18
142
18
157
1.15
0.17
1.2
1.2
—
1.9
—
0
7
49
456
1.08
0.17
2.2
2.5
—
13.6
—
0
25
5
67
0.74
0.17
1.6
2.7
—
—
—
0
0
17
148
1.15
0.17
1.2
1.2
—
6.2
—
0
21
20
180
1.11
0.13
2.0
1.9
—
—
—
0
0
17
189
0.90
0.12
1.4
2.1
—
—
—
0
0
11
125
0.88
0.10
1.2
1.1
—
—
—
0
0
21
193
1.09
0.10
1.3
1.3
—
—
—
0
0
5
45
1.11
0.10
1.2
1.3
—
—
—
0
0
5
45
1.11
0.10
1.2
1.3
—
—
—
0
0
10
114
0.88
0.09
1.2
1.2
—
1.1
—
0
8
5
47
1.06
0.09
1.2
1.1
—
—
—
0
0
24
224
1.07
0.08
2.1
1.9
—
—
—
0
0
7
66
1.06
0.08
1.1
1.0
—
—
—
0
0
11
98
1.12
0.07
1.7
1.5
—
—
—
0
0
15
137
1.10
0.07
1.8
1.6
—
—
—
0
0
8
91
0.88
0.06
1.0
1.5
—
—
—
0
0
8
91
0.88
0.06
1.0
1.5
—
—
—
0
0
8
92
0.87
0.06
1.0
1.5
—
—
—
0
0
11
101
1.09
0.04
1.2
1.5
—
—
—
0
0
55
539
1.02
0.03
2.4
2.5
56.1
66.9
ml/min/173m2
1.23
25
201
24
231
1.04
0.03
2.2
1.7
—
—
—
0
0
11
118
0.93
0.02
1.1
1.4
—
—
—
0
0
83
819
1.01
0.02
11.1
6.9
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
9
92
0.98
0.00
1.1
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
69
0.87
0.00
1.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
5
56
0.89
0.00
1.0
1.7
7.0
3.7
mg/l
—
5
56
9
92
0.98
0.00
1.1
1.5
—
—
—
0
0
7
73
0.96
0.00
1.6
1.5
—
—
—
0
0
9
90
1.00
0.00
1.1
1.5
—
—
—
0
0
8
81
0.99
0.00
4.1
3.1
52.8
18.4
u/ml
—
8
81
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_SCNDPOLYCYTHAEMIA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_SCNDPOLYCYTHAEMIA | 2.337 [1.94, 2.81] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.556 |
During the follow-up period (1.1.1998 — 31.12.2019), 330 out of 1298 females with D3_SCNDPOLYCYTHAEMIA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_SCNDPOLYCYTHAEMIA | 1.929 [1.65, 2.25] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 574 out of 2522 males with D3_SCNDPOLYCYTHAEMIA died.
Mortality risk
Mortality risk for people of age
years, who have D3_SCNDPOLYCYTHAEMIA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.314% | 0.369% |
| 5 | 1.509% | 2.132% |
| 10 | 3.477% | 5.162% |
| 15 | 6.641% | 10.023% |
| 20 | 12.368% | 16.089% |
Relationships between endpoints
↥Index endpoint: D3_SCNDPOLYCYTHAEMIA – Secondary polycythaemia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data